- Home
- NEUP vs ASBP Comparison
NEUP vs ASBP Comparison
Compare NEUP & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- ASBP
- Stock Information
- Founded
- NEUP 1996
- ASBP 2021
- Country
- NEUP United States
- ASBP United States
- Employees
- NEUP N/A
- ASBP N/A
- Industry
- NEUP
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- ASBP Health Care
- Exchange
- NEUP Nasdaq
- ASBP Nasdaq
- Market Cap
- NEUP 12.7M
- ASBP 11.9M
- IPO Year
- NEUP N/A
- ASBP N/A
- Fundamental
- Price
- NEUP $6.87
- ASBP $0.38
- Analyst Decision
- NEUP Strong Buy
- ASBP
- Analyst Count
- NEUP 1
- ASBP 0
- Target Price
- NEUP $21.00
- ASBP N/A
- AVG Volume (30 Days)
- NEUP 29.5K
- ASBP 36.0M
- Earning Date
- NEUP 06-17-2025
- ASBP 05-14-2025
- Dividend Yield
- NEUP N/A
- ASBP N/A
- EPS Growth
- NEUP N/A
- ASBP N/A
- EPS
- NEUP 0.00
- ASBP N/A
- Revenue
- NEUP $15,662,715.00
- ASBP N/A
- Revenue This Year
- NEUP N/A
- ASBP N/A
- Revenue Next Year
- NEUP N/A
- ASBP N/A
- P/E Ratio
- NEUP $4,008.24
- ASBP N/A
- Revenue Growth
- NEUP N/A
- ASBP N/A
- 52 Week Low
- NEUP $2.90
- ASBP $0.22
- 52 Week High
- NEUP $126.00
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- NEUP N/A
- ASBP N/A
- Support Level
- NEUP N/A
- ASBP N/A
- Resistance Level
- NEUP N/A
- ASBP N/A
- Average True Range (ATR)
- NEUP 0.00
- ASBP 0.00
- MACD
- NEUP 0.00
- ASBP 0.00
- Stochastic Oscillator
- NEUP 0.00
- ASBP 0.00
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About ASBP Aspire Biopharma Holdings Inc. Common Stock
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.